Fintel reports that on October 16, 2026, William Blair initiated coverage of Revolution Medicines (NASDAQGS:RVMD) (BIT:1RVMD) with a Outperform recommendation.Revolution Medicines, Inc., based in the United States, operates within the biotechnology industry, specifically focusing

William Blair Initiates Coverage of Revolution Medicines at Outperform

Key PointsRevolution Medicines recently made a breakthrough in oncology.

These 2 Stocks Have Run Circles Around the Magnificent Seven This Year, and Wall Street Says There Is More Upside Ahead

(RTTNews) - Revolution Medicines (RVMD) on Thursday said the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for RASONQUE (daraxonrasib) to treat adults with metastatic pancreatic adenocarcinoma who have re

Revolution Medicines' Pancreatic Cancer Drug Gets Positive EU Review 

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Revolution Medicines, Inc. News